Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protagonist Therapeutics, IncPTGX · Entity 3552 | Chief Financial Officer | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protagonist Therapeutics, Inc
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,003 |
Ending reported balance
After 2026-09-30 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-09-30 · Exercise / conversion · Acquired 9,229 · Balance 68,232 F1: The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. Row 2 · 2026-09-30 · Exercise / conversion · Acquired 28,438 · Balance 96,670 F1: The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. Row 3 · 2026-09-30 · Exercise / conversion · Acquired 15,650 · Balance 112,320 F1: The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. Row 4 · 2026-09-30 · Exercise / conversion · Acquired 5,312 · Balance 117,632 F1: The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. Row 5 · 2026-09-30 · Sale · Disposed 12,595 · Balance 105,037 F1: The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $140.21 to $143.31. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Row 6 · 2026-09-30 · Sale · Disposed 46,034 · Balance 59,003 F1: The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $140.16 to $143.45. Upon request by the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.98 · Expires 2035-01-01 | Direct | 29,291 |
Reported balance
After 2026-09-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-30 · Exercise / conversion · Disposed 9,229 · Balance 29,291 F4: The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.42 · Expires 2034-01-01 | Direct | 49,562 |
Reported balance
After 2026-09-30 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-30 · Exercise / conversion · Disposed 28,438 · Balance 49,562 F5: The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.19 · Expires 2032-04-17 | Direct | 51,150 |
Reported balance
After 2026-09-30 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-30 · Exercise / conversion · Disposed 15,650 · Balance 51,150 F6: The stock option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.17 · Expires 2033-01-15 | Direct | 25,235 |
Reported balance
After 2026-09-30 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-30 · Exercise / conversion · Disposed 5,312 · Balance 25,235 F7: The stock option vests in 48 equal monthly installments following January 16, 2023, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.
F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $140.21 to $143.31. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $140.16 to $143.45. Upon request by the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4: The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.
F5: The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.
F6: The stock option is fully vested.
F7: The stock option vests in 48 equal monthly installments following January 16, 2023, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2024 Filed Jan 5, 2024 01:07 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-001489 · tm241954-1_4seq1.xml · nonDerivative · entry 1 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,036 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in three equal annual installments on January 15, 2025, 2026 and 2027, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:48 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Tax withholdingCommon Stock | 4,150 | $26.07 | $108,190.50 |
DisclosureSEC source: 0001104659-23-067689 · tm2317724-1_4seq1.xml · nonDerivative · entry 2 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,036 F3 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of PSUs. F2 · balance_after: The shares of common stock reported on this Form 4 are subject to a lock-up agreement between the reporting person and J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., dated April 4, 2023 (the "Lock-up Date") pursuant to which the shares of common stock reported herein cannot be sold for 60 days following the Lock-up Date. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:48 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-067689 · tm2317724-1_4seq1.xml · nonDerivative · entry 1 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,186 F1 · shares: Represents settlement by the Issuer of performance stock units ("PSUs") granted to the Reporting Person under the Company's 2016 Equity Incentive Plan on May 31, 2022, which vested based on the Issuer's achievement of corporate performance objectives. F2 · balance_after: The shares of common stock reported on this Form 4 are subject to a lock-up agreement between the reporting person and J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., dated April 4, 2023 (the "Lock-up Date") pursuant to which the shares of common stock reported herein cannot be sold for 60 days following the Lock-up Date. Read SEC document |
| April 18, 2023 Filed Apr 19, 2023 20:28 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Tax withholdingCommon Stock | 1,189 | $23.21 | $27,596.69 |
DisclosureSEC source: 0001104659-23-047208 · tm2312473-2_4seq1.xml · nonDerivative · entry 1 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,186 F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the release of 3,437 vested restricted stock units on April 18, 2023. F2 · balance_after: The shares of common stock reported on this Form 4 are subject to a lock-up agreement between the reporting person and J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., dated April 4, 2023 (the "Lock-up Date") pursuant to which the shares of common stock reported herein cannot be sold for 60 days following the Lock-up Date. Read SEC document |
| January 16, 2023 Filed Jan 19, 2023 00:53 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 63,750 | $0.00 Strike: $12.17 | $0.00 |
DisclosureSEC source: 0001104659-23-004725 · tm233829-3_4seq1.xml · derivative · entry 2 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,750 Underlying: Common Stock · 63,750 shares Expires 2033-01-15 F2 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| January 16, 2023 Filed Jan 19, 2023 00:53 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 10,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004725 · tm233829-3_4seq1.xml · nonDerivative · entry 1 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,375 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in three annual installments on January 15, 2024, 2025 and 2026. Read SEC document |
| April 18, 2022 Filed Apr 19, 2022 23:48 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 82,500 | $0.00 Strike: $19.19 | $0.00 |
DisclosureSEC source: 0001104659-22-047468 · tm2212815-3_4seq1.xml · derivative · entry 2 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2032-04-18 F2 · derivative.exercise_date: The stock option represents a right to purchase a total of 82,500 shares of the Issuer's common stock, one quarter of which will vest on April 18, 2023, with the remaining three quarters vesting in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| April 18, 2022 Filed Apr 19, 2022 23:48 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-047468 · tm2212815-3_4seq1.xml · nonDerivative · entry 1 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 F1 · shares: Represents grant of restricted stock units payable solely in shares of the Issuer's common stock that will vest in four annual installments on April 18, 2023, 2024, 2025 and 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.